NCT07816289Not yet recruitingPhase 3
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)
A Phase 3, Randomized, Double-masked, Multicenter, Active Comparator-controlled Trial to Investigate the Efficacy and Safety of Monthly Intravitreal OLN324 in Adult Participants With Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Source: ClinicalTrials.gov · Last updated 11 Sept 2026
Brief summary (registry, in English)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 7 Sept 2026
- Start date
- 15 Oct 2026
- Primary completion date
- 15 Dec 2028
- Lead sponsor
- Ollin Biosciences, Inc.
- Diseases
- Macular degeneration
- NCT number
- NCT07816289
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 400
- From 15 Oct 2026 to the primary completion date, 15 Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of cataract surgery in the study eye within 90 days of Screening
- Has uncontrolled hypertension
- Has had a stroke or myocardial infarction within 180 days
Other
- Be pregnant or breastfeeding
- Has uncontrolled glaucoma in the study eye
- Additional exclusion criteria apply
Who the study is looking for
- Capable of giving signed informed consent
- Be ≥50 years of age
- Treatment-naive nAMD in the study eye with active subfoveal choroidal neovascularization (CNV)
- Have a decrease in vision in the study eye due to nAMD, with best corrected visual acuity of 78 to 24 letters
- Additional inclusion criteria apply
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.